Sex difference in response to non-small cell lung cancer immunotherapy: an updated meta-analysis.

ABSTRACT:

Background

Studying sex differences in the efficacy of immunotherapy may contribute to the practice of the precision medicine, especially in non-small cell lung cancer (NSCLC), a kind of cancer with sexual bimorphism.

Methods

Published randomized controlled trials (RCTs), published by PubMed, Medline, Embase, and Scopus, before 15 June 2022, testing immunotherapy (CTLA-4 or PD-1/L1 inhibitor alone, combination or with chemotherapy) versus non-immunotherapy (receiving chemotherapy or placebo only) were included to assess different efficacy between males and females. The primary endpoint was overall survival (OS). This meta-analysis was registered with PROSPERO (CRD42022298439).

Results

Sixteen RCTs, involving 10,155 patients with advanced NSCLC, was collected in this m

SUBMITTER: Liang J 

PROVIDER: S-EPMC9518269 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature